Is there a role for radiation therapy in the management of H  rthle cell XXXX ?

@entity1 @entity5 @entity189 @entity3 @entity259
PURPOSE: To determine the role that radiation therapy may have in the management of resected, unresectable, and metastatic H  rthle cell @entity189 . METHODS AND MATERIALS: Retrospective review of 18 @entity1 receiving radiation therapy for H  rthle cell @entity259 . The diagnosis was established in 10 @entity1 and 8 @entity1 between November 1943 and January 1995. Median age was 57.9 years. Initially, 5 @entity1 received adjuvant radiation therapy, 7 received salvage radiation therapy for unresectable recurrent disease, and 6 received palliative radiation therapy for distant @entity3 . Median follow-up was 107.1 months (range 15.7-351 months). The Kaplan-Meier method was used to calculate and estimate overall survival, cause-specific survival, and @entity5 control rate. RESULTS: The 5-year overall and cause-specific survival rates were 66.7% (SE 11.1%) and 71.8% (SE 10.7%), respectively. Adjuvant radiation therapy was successful in preventing recurrence in 4 of 5 @entity1 . Salvage radiation therapy was successful in 3 of 5 @entity1 treated with external beam radiation therapy. Palliative radiation therapy provided sustained symptomatic relief at 67% of irradiated sites. CONCLUSIONS: H  rthle cell @entity259 is a radiosensitive @entity5 . Radiation therapy may provide palliative relief from symptomatic @entity3 , control recurrent @entity5 , and prevent recurrence of advanced resected @entity5 .
